Latest Insider Transactions at Ocular Therapeutix, Inc (OCUL)
This section provides a real-time view of insider transactions for Ocular Therapeutix, Inc (OCUL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of OCULAR THERAPEUTIX, INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of OCULAR THERAPEUTIX, INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 25
2024
|
Peter Kaiser Chief Development Officer |
SELL
Open market or private sale
|
Direct |
2,897
-1.34%
|
$26,073
$9.01 P/Share
|
|
Nov 25
2024
|
Jeffrey S. Heier Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,948
-1.08%
|
$26,532
$9.01 P/Share
|
|
Nov 25
2024
|
Pravin Dugel Director |
SELL
Open market or private sale
|
Direct |
20,680
-2.55%
|
$186,120
$9.01 P/Share
|
|
Nov 25
2024
|
Sanjay Nayak Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
1,814
-1.03%
|
$16,326
$9.0 P/Share
|
|
Oct 07
2024
|
Todd Anderman Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
98,700
+50.0%
|
-
|
|
Oct 02
2024
|
Jeffrey S. Heier Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+26.88%
|
-
|
|
Oct 02
2024
|
Peter Kaiser Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+31.65%
|
-
|
|
Aug 29
2024
|
Donald Notman Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,034
+5.02%
|
-
|
|
Aug 23
2024
|
Pravin Dugel Director |
SELL
Open market or private sale
|
Direct |
20,880
-2.51%
|
$187,920
$9.02 P/Share
|
|
Aug 23
2024
|
Sanjay Nayak Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
1,832
-1.03%
|
$16,488
$9.02 P/Share
|
|
Jul 24
2024
|
Richard L Md Lindstrom Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+6.87%
|
-
|
|
Jul 24
2024
|
Charles M Warden Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+14.21%
|
-
|
|
Jul 24
2024
|
Leslie J. Williams Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+24.28%
|
-
|
|
Jul 24
2024
|
Merilee Raines Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+26.71%
|
-
|
|
Jul 24
2024
|
Seung Suh Hong Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+26.71%
|
-
|
|
Jul 24
2024
|
Adrienne L Graves Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+25.0%
|
-
|
|
Jun 01
2024
|
Nadia Waheed Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
141,666
+50.0%
|
-
|
|
May 23
2024
|
Pravin Dugel Director |
SELL
Open market or private sale
|
Direct |
21,626
-2.53%
|
$108,130
$5.79 P/Share
|
|
May 23
2024
|
Sanjay Nayak Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
2,274
-1.26%
|
$11,370
$5.84 P/Share
|
|
Feb 27
2024
|
Richard L Md Lindstrom Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,302
+9.49%
|
$242,416
$8.8 P/Share
|
|
Feb 26
2024
|
Summer Road LLC |
BUY
Open market or private purchase
|
Indirect |
930,851
+9.78%
|
$6,515,957
$7.52 P/Share
|
|
Feb 22
2024
|
Sanjay Nayak Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,300
+30.81%
|
-
|
|
Feb 22
2024
|
Pravin Dugel Director |
BUY
Grant, award, or other acquisition
|
Direct |
854,979
+50.0%
|
-
|
|
Feb 05
2024
|
Philip C. Strassburger General Counsel |
BUY
Open market or private sale
|
Direct |
6,029
+3.6%
|
$24,116
$4.86 P/Share
|
|
Feb 05
2024
|
Christopher G White Chief Business Officer |
BUY
Open market or private sale
|
Direct |
5,910
+4.56%
|
$23,640
$4.86 P/Share
|
|
Feb 05
2024
|
Donald Notman Officer |
BUY
Open market or private sale
|
Direct |
6,212
+3.08%
|
$24,848
$4.86 P/Share
|
|
Feb 05
2024
|
Rabia Gurses Ozden Chief Medical Officer |
BUY
Open market or private sale
|
Direct |
6,346
+3.98%
|
$25,384
$4.86 P/Share
|
|
Feb 05
2024
|
Antony C. Mattessich President and CEO |
BUY
Open market or private sale
|
Direct |
19,642
+3.23%
|
$78,568
$4.86 P/Share
|
|
Feb 03
2024
|
Philip C. Strassburger General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
58,304
+25.82%
|
-
|
|
Feb 03
2024
|
Christopher G White Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,980
+23.58%
|
-
|
|
Feb 03
2024
|
Donald Notman Officer |
BUY
Grant, award, or other acquisition
|
Direct |
61,636
+23.42%
|
-
|
|
Feb 03
2024
|
Rabia Gurses Ozden Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,633
+29.48%
|
-
|
|
Feb 03
2024
|
Antony C. Mattessich President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
180,400
+22.87%
|
-
|
|
Jan 31
2024
|
Antony C. Mattessich President and CEO |
SELL
Open market or private sale
|
Direct |
18,338
-4.11%
|
$73,352
$4.95 P/Share
|
|
Jan 31
2024
|
Christopher G White Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,147
-5.43%
|
$20,588
$4.95 P/Share
|
|
Jan 31
2024
|
Philip C. Strassburger General Counsel |
SELL
Open market or private sale
|
Direct |
6,831
-5.89%
|
$27,324
$4.95 P/Share
|
|
Jan 31
2024
|
Rabia Gurses Ozden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,764
-7.72%
|
$31,056
$4.95 P/Share
|
|
Jan 31
2024
|
Donald Notman Officer |
SELL
Open market or private sale
|
Direct |
6,433
-4.4%
|
$25,732
$4.95 P/Share
|
|
Dec 14
2023
|
Summer Road LLC |
BUY
Open market or private purchase
|
Indirect |
1,538,461
+16.72%
|
$4,615,383
$3.25 P/Share
|
|
Aug 30
2023
|
Antony C. Mattessich President and CEO |
BUY
Open market or private purchase
|
Indirect |
6,500
+50.0%
|
$19,500
$3.81 P/Share
|
|
Jul 10
2023
|
Adrienne L Graves Director |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+50.0%
|
-
|
|
Jul 07
2023
|
Rabia Gurses Ozden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
832
-0.82%
|
$3,328
$4.93 P/Share
|
|
Jun 14
2023
|
Charles M Warden Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+16.56%
|
-
|
|
Jun 14
2023
|
Richard L Md Lindstrom Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+9.06%
|
-
|
|
Jun 14
2023
|
Merilee Raines Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+36.44%
|
-
|
|
Jun 14
2023
|
Leslie J. Williams Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+32.06%
|
-
|
|
Jun 14
2023
|
Jeffrey S. Heier Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+16.68%
|
-
|
|
Jun 14
2023
|
Seung Suh Hong Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+36.44%
|
-
|
|
Feb 06
2023
|
Christopher G White Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,829
-5.79%
|
$23,316
$4.24 P/Share
|
|
Feb 06
2023
|
Antony C. Mattessich President and CEO |
SELL
Open market or private sale
|
Direct |
19,669
-4.22%
|
$78,676
$4.24 P/Share
|